Anatara Lifesciences (ASX: ANR) reaches milestone in progression of Phase II IBS trial (w/ David Brookes)

Small Caps

Anatara Lifesciences (ASX: ANR) executive chair Dr David Brookes joins Small Caps to discuss the progress of the company's trial of a potential treatment for the aptly named irritable bowel syndrome (IBS).

The company recently received the go-ahead to enrol patients for the second stage of its pivotal GaRP-IBS trial, which is to be conducted at 5 sites in Melbourne, Sydney and Brisbane.

Anatara has received highly encouraging findings from Stage 1 of the GaRP-IBS clinical trial and Stage 2 of the trial will progress these promising developments to further efficacy claims .

Under the trial guidelines, participants will be randomly placed into two groups to take either the optimum dose of the GaRP product selected from Stage 1 or the placebo.

It is expected that each patient will take approximately three months to complete the trial, which involves a wash-out period and then 8 weeks on the product or placebo.

While IBS is a fairly common issue, with an estimated 5% to 10% of the world's population currently be suffering from the syndrome, many of those people may well be unaware of what the issue is.

April is annual IBS Awareness Month with the aim this year to help destigmatise the different types of syndrome people may be suffering.

Approximately 1 in 5 Australians experience the unpleasant symptoms of irritable bowel syndrome (IBS) at some time.

Articles:
https://smallcaps.com.au/anatara-lifesciences-garp-therapy-trial-extension-treat-irritable-bowel-syndrome/
https://smallcaps.com.au/ibs-awareness-month-anatara-lifesciences-trial-offers-hope-millions/

For more information on Anatara Lifesciences:
https://smallcaps.com.au/stocks/asx-anr/

See omnystudio.com/listener for privacy information.